Ayala Pharmaceuticals, Inc. Common Stock
AYLA
AYLA was delisted on the 18th of January, 2023.
11 hedge funds and large institutions have $946K invested in Ayala Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 6 closing their positions.
21% less funds holding
Funds holding: 14 → 11 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
63% less capital invested
Capital invested by funds: $2.58M → $946K (-$1.63M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.41K |
| 2 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$6.49K |
| 3 |
Renaissance Technologies
New York
|
+$3.63K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$655 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CL
CSS LLC
Chicago,
Illinois
|
-$64K |
| 2 |
CS
Clear Street
New York
|
-$39K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$24K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$23K |
| 5 |
VF
Virtu Financial
New York
|
-$19K |
AYLA Hedge Fund Activity: Q4 2022 in Review
11 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Ayala Pharmaceuticals, Inc. Common Stock (AYLA) for Q4 2022, worth a combined $946K — down 63% from $2.58M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of AYLA and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $7.41K. The largest seller was CSS LLC, exiting entirely with an estimated $64K sold.
- 11 institutional investors held Ayala Pharmaceuticals, Inc. Common Stock (AYLA) as of Q4 2022, down from 14 in Q3 2022.
- Funds reported $946K of Ayala Pharmaceuticals, Inc. Common Stock stock for Q4 2022, down 63% quarter-over-quarter.
- 3 funds opened new Ayala Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 6 closed out, a net change of -3 holders.
- The largest Ayala Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was Citadel Advisors, an estimated $7.41K added.
- The largest Ayala Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was CSS LLC, an estimated $64K sold.
Based on aggregated 13F filings for Q4 2022.